Systematic Evaluation Meta-Analysis of the Efficacy of Recombinant Human Endostatin Combined with Gemcitabine and Cisplatin in Non-Small-Cell Lung Cancer

Table 3

Forest map of meta-analysis of benefit rate between groups.

Study details	Experimental		Control		Weight (%)	Risk ratio
	Events	Total	Events	Total		MH, fixed, 95% CI
Si Feng, 2012	32	40	18	32	3.5	1.42 [1.01, 2.00]
Fu Hao, 2015	28	32	22	28	4.1	1.11 [0.88, 1.41]
Jian-Wu Liu, 2012	25	30	19	30	3.3	1.32 [0.96, 1.80]
Liu Tao, 2015	31	32	24	32	4.2	1.29 [1.05, 1.59]
Song Wenxian, 2018	25	30	22	30	3.9	1.14 [0.87, 1.49]
Yuan-yuan Zhang, 2014	22	31	19	28	3.5	1.05 [0.74, 1.47]
Xu Li, 2017	30	35	22	35	3.9	1.36 [1.02, 1.82]
Fang Li, 2017	20	23	12	23	2.3	1.54 [1.04, 2.28]
Li Lihua, 2016	23	23	22	23	4.0	1.04 [0.93, 1.18]
LuanWenQiang, 2012	20	25	14	27	2.4	1.54 [1.02, 2.33]
Relapsed Chicken, 2012	87	94	71	90	12.8	1.17 [1.04, 1.32]
Hi-Feng Wang, 2018	28	34	21	30	3.9	1.18 [0.89, 1.56]
Wang Fang, 2011	27	31	22	29	4.0	1.15 [0.90, 1.47]
Mention, 2010	20	20	18	20	3.3	1.11 [0.93, 1.31]
Xie Yanru, 2008	17	22	19	26	3.1	1.06 [0.76, 1.46]
Tany, 2013	34	38	24	38	4.2	1.42 [1.09, 1.85]
Xiao-jing Jia, 2017	16	20	12	20	2.1	1.33 [0.88, 2.03]
Deng Qingping, 2011	11	17	6	18	1.0	1.94 [0.92, 4.08]

Heterogeneity: chi² = 1.75, d_f = 2 ( = 0.42), and I² = 0%. Test for overall effect: Z = 1.23 ( = 0.22).